Xcout IntelMinerva Neurosciences, Inc
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Subscribe to see Minerva Neurosciences, Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Minerva Neurosciences, Inc at a glance
Minerva Neurosciences, Inc is a biotechnology company headquartered in Burlington, United States, founded in 2007. It is publicly listed (NERV) with a market capitalisation of $225.5M. Xcout tracks 18 named people at Minerva Neurosciences, Inc, including Remy Luthringer (Executive Chairman, CEO & Member of Scientific Advisory Board).
Minerva Neurosciences, Inc leadership
- Remy LuthringerExecutive Chairman, CEO & Member of Scientific Advisory Board
- Joseph ReillySenior Vice President & Chief Operating Officer
- Frederick W. AhlholmSenior Vice President, Chief Financial Officer & Secretary
- Frederick AhlholmChief Financial Officer
- Michael DavidsonMember of Scientific Advisory Board & Chief Medical Officer
- Anthony AliquoChief Accounting Officer & Principal Accounting Officer
12 more named people on record for Minerva Neurosciences, Inc, with roles, board committees and tenure — see the full roster →
Minerva Neurosciences, Inc competitors
A few of Minerva Neurosciences, Inc's closest competitors — see the full list of competitors and alternatives →
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Get Minerva Neurosciences, Inc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Minerva Neurosciences, Inc in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access